Jim Cramer’s renewed endorsement of Moderna signals growing confidence in its mRNA pipeline and potential stock upside
Executive summary: Jim Cramer stated he now likes having a position in Moderna for the first time in ages. His endorsement may sway investor sentiment and highlights recent positive developments in Moderna's mRNA pipeline.
Who is involved: Jim Cramer, Moderna, retail investors
Likely next: Increased retail interest could exert upward pressure on Moderna's stock, prompting further analyst commentary.
Jim Cramer, a prominent TV personality and former hedge fund manager, said he now likes having a position in Moderna for the first time in ages. This shift may reflect recent positive developments such as favorable FDA votes or pipeline updates. While no specific financial details were provided, the comment could influence retail investor sentiment toward the biotech stock.
Timeline
- — Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” (Yahoo Finance)
- — Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? (Yahoo Finance)
Analysis — what this means
Likely next events
- Potential increase in retail trading volume for Moderna
- Further analyst commentary on Moderna
Sectors affected
- Biotechnology
- Pharmaceutical
Historical parallels
- Similar commentator endorsements preceding stock rallies (e.g., Jim Cramer on Tesla in 2020)
Key entities
Sources
Open the full interactive case file on Beyond →